Australia’s therapeutic cannabis sector is entering a new phase of regulatory scrutiny. According to Cannabis News Australia, the council responsible for Therapeutic Goods Order 93 (TGO 93) held its inaugural meeting recently, with the explicit goal of raising quality standards for medicinal cannabis products across the country.
What TGO 93 Means for Cannabis Quality
TGO 93 is the regulatory framework governing medicinal cannabis quality in Australia, administered by the Therapeutic Goods Administration (TGA). It sets specifications for everything from cannabinoid content and stability to microbial contamination limits. The council’s first meeting signals that regulators are preparing to tighten these requirements—likely in response to growing concerns about product consistency and contamination in the Australian market.
For cultivators supplying the Australian medicinal market, whether domestically or through international exports, this development demands attention. Australia has become a significant destination for cannabis imports, particularly from producers in Canada, Europe, and increasingly other regions seeking access to a well-regulated, high-value patient market.
The Microbial Challenge in Export Markets
Stricter quality standards invariably mean more rigorous testing for microbial contaminants like mold and yeast. Total Yeast and Mold (TY&M) counts are among the most common reasons cannabis shipments fail quality specifications in pharmaceutical-grade markets. For cultivators, a single failed batch can mean lost revenue, damaged reputation, and exclusion from lucrative supply contracts.
The challenge is particularly acute for flower products. Unlike extracts, cannabis flower cannot be processed to eliminate contaminants without affecting the therapeutic compounds that make it valuable. Traditional remediation methods force cultivators into difficult tradeoffs: irradiation raises concerns among patients and physicians, while chemical treatments can leave residues or alter product characteristics.
Cold Plasma: Meeting Pharmaceutical Standards Without Compromise
Cold plasma remediation technology offers cultivators a path to compliance that doesn’t require sacrificing product quality. The technology works by generating reactive oxygen species that neutralize mold, yeast, and bacteria on the cellular level—without heat, chemicals, or ionizing radiation.
For cultivators targeting markets like Australia where TGO 93 compliance is mandatory, cold plasma provides several critical advantages. The process preserves THC potency and terpene profiles, maintaining the full therapeutic value of the flower. It leaves no chemical residues, meeting the stringent purity requirements of pharmaceutical-grade specifications. And because it doesn’t involve irradiation, it avoids the labeling and patient perception issues that can limit market access for irradiated products.
Preparing for Elevated Standards
The TGO 93 council’s work is still in early stages, and specific regulatory changes have yet to be announced. However, the direction is clear: Australia intends to position itself as a premium medicinal cannabis market with quality standards to match. Cultivators who invest in compliance infrastructure now will be better positioned when new requirements take effect.
As global cannabis markets mature, the ability to consistently pass microbial testing at pharmaceutical thresholds will separate viable commercial operations from those left behind. Solutions like Curaflo’s cold plasma systems give cultivators the tools to meet these evolving standards while preserving what makes their flower valuable in the first place.
Learn more about cold plasma remediation at curaflo.tech.
Leave a Reply